Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc
Journal website https://jmc.elmerpub.com

Case Report

Volume 16, Number 11, November 2025, pages 444-452

Eccrine Carcinoma Mimicking Breast Cancer: Diagnostic Challenges and Hormone Therapy as an Emerging Treatment

Figures

Figure 1.
Figure 1. Histologic features of eccrine carcinoma at the initial diagnosis. Basaloid cells are infiltrating the dermis. (original magnification × 100).
Figure 2.
Figure 2. Immunostain for ER (original magnification × 100). ER: estrogen receptor.
Figure 3.
Figure 3. Immunostain for PR (original magnification × 100). PR: progesterone receptor.
Figure 4.
Figure 4. Immunostain for mammaglobin (original magnification × 100).
Figure 5.
Figure 5. Histologic features of eccrine cell carcinoma at excision. The carcinoma is infiltrative, largely involving the dermis (original magnification × 50).
Figure 6.
Figure 6. Histologic features of eccrine cell carcinoma at excision. (original magnification × 200).
Figure 7.
Figure 7. Histologic features of eccrine cell carcinoma at excision. Extensive perineural invasion. (original magnification × 400).
Figure 8.
Figure 8. Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) scan of the whole body demonstrates increased FDG avidity in (a) left level 1 lymph node, (b) left level 2 lymph node, (c) left internal mammary lymph node, (d) mediastinal/paratracheal lymph node, and (e) left malar soft-tissue nodule (yellow arrows), concerning for metastatic disease. (f) No evidence of increased FDG avidity within the breast tissues to suggest neoplastic disease.